Mitophagy in Macrophages: A Metabolic Checkpoint in Inflammation‐to‐Repair Transition in Atherosclerosis

Atherosclerosis is the leading cause of cardiovascular morbidity and mortality worldwide, driven not only by lipid accumulation but also by chronic inflammation and defective tissue repair. Among immune cells within plaques, macrophages orchestrate both inflammatory injury and reparative responses, and their fate is critically regulated by mitochondrial quality control. Damaged mitochondria release mitochondrial reactive oxygen species and mitochondrial DNA, which activate innate immune pathways, such as the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome and the cyclic GMP-AMP synthase-stimulator of interferon genes pathway, thereby amplifying inflammation. Mitophagy, the selective clearance of dysfunctional mitochondria, has emerged as a metabolic checkpoint determining whether macrophages sustain inflammation or transition toward repair. Key signaling axes, including phosphatase and tensin homolog (PTEN)-induced kinase 1/Parkin, BNIP3 (BCL2/adenovirus E1B 19-kDa interacting protein 3)/NIX (NIP3-like protein X), and FUNDC1 (FUN14 domain-containing protein 1), converge to limit mitochondrial reactive oxygen species and mitochondrial DNA release, suppress innate immune activation, and preserve oxidative metabolism. By maintaining energy balance, mitophagy supports efferocytosis, extracellular matrix deposition, and fibrous cap stabilization, whereas its impairment drives necrotic core expansion and plaque vulnerability. Preclinical studies demonstrate that mitophagy can be therapeutically modulated by small molecules (metformin and resveratrol), natural products (salidroside), gene-based and nanoparticle approaches, and lifestyle interventions. This review summarizes mechanistic insights into macrophage mitophagy, emphasizes its role as a metabolic checkpoint in the inflammation-to-repair transition, and discusses translational opportunities and challenges in targeting this pathway to stabilize vulnerable plaques.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-03-28
DOI
https://doi.org/10.1161/jaha.125.048103
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mitophagy in Macrophages: A Metabolic Checkpoint in Inflammation‐to‐Repair Transition in Atherosclerosis

J H Zhou, Hao Wang, Hanxiu Liu, Ni He et al.
Journal of the American Heart Association
Autophagy in Disease and Therapy
article

Mitophagy in Macrophages: A Metabolic Checkpoint in Inflammation‐to‐Repair Transition in Atherosclerosis

J H Zhou, Hao Wang, Hanxiu Liu, Ni He, Xiaoling Zhang, Zhongwei Liu, Sen Ma
article en

Abstract

Atherosclerosis is the leading cause of cardiovascular morbidity and mortality worldwide, driven not only by lipid accumulation but also by chronic inflammation and defective tissue repair. Among immune cells within plaques, macrophages orchestrate both inflammatory injury and reparative responses, and their fate is critically regulated by mitochondrial quality control. Damaged mitochondria release mitochondrial reactive oxygen species and mitochondrial DNA, which activate innate immune pathways, such as the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome and the cyclic GMP-AMP synthase-stimulator of interferon genes pathway, thereby amplifying inflammation. Mitophagy, the selective clearance of dysfunctional mitochondria, has emerged as a metabolic checkpoint determining whether macrophages sustain inflammation or transition toward repair. Key signaling axes, including phosphatase and tensin homolog (PTEN)-induced kinase 1/Parkin, BNIP3 (BCL2/adenovirus E1B 19-kDa interacting protein 3)/NIX (NIP3-like protein X), and FUNDC1 (FUN14 domain-containing protein 1), converge to limit mitochondrial reactive oxygen species and mitochondrial DNA release, suppress innate immune activation, and preserve oxidative metabolism. By maintaining energy balance, mitophagy supports efferocytosis, extracellular matrix deposition, and fibrous cap stabilization, whereas its impairment drives necrotic core expansion and plaque vulnerability. Preclinical studies demonstrate that mitophagy can be therapeutically modulated by small molecules (metformin and resveratrol), natural products (salidroside), gene-based and nanoparticle approaches, and lifestyle interventions. This review summarizes mechanistic insights into macrophage mitophagy, emphasizes its role as a metabolic checkpoint in the inflammation-to-repair transition, and discusses translational opportunities and challenges in targeting this pathway to stabilize vulnerable plaques.

Journal of the American Heart Association
Yan'an University (CN), Xi'an Medical University (CN), Precision for Medicine (United States) (US)
Openalex Percentile: Top 4%
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.